Unknown

Dataset Information

0

Chimeric Antigen Receptors for T-Cell Malignancies.


ABSTRACT: Development of chimeric antigen receptor (CAR)-modified T cells for the treatment of T-lineage leukemia and lymphoma has encountered several unique challenges. The most widely expressed tumor antigen targets for malignant T cells are often also expressed on non-malignant T cells. Transducing T cells with CARs targeted to these shared antigens can therefore promote over-activation or fratricide of CAR T cells, reducing their therapeutic potency. If fratricide is resolved, clinical CAR T cell activity may eliminate normal T-cell subsets and cause temporary immunosuppression. In this review, we summarize the preclinical development of CAR-based therapies for T-cell malignancies and discuss strategies to minimize toxicities associated with on-target fratricide and off-tumor activity.

SUBMITTER: Scherer LD 

PROVIDER: S-EPMC6411696 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4684946 | biostudies-literature
| S-EPMC5738277 | biostudies-literature
| S-EPMC11345381 | biostudies-literature
| S-EPMC8807386 | biostudies-literature
| S-EPMC9939332 | biostudies-literature
| S-EPMC5790337 | biostudies-literature
| S-EPMC5302909 | biostudies-other
| S-EPMC9121778 | biostudies-literature
| S-EPMC4412125 | biostudies-literature
| S-EPMC4843171 | biostudies-literature